0001104659-20-103455.txt : 20201009 0001104659-20-103455.hdr.sgml : 20201009 20200909161554 ACCESSION NUMBER: 0001104659-20-103455 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20200909 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nabriva Therapeutics plc CENTRAL INDEX KEY: 0001641640 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 56 FITZWILLIAM SQUARE CITY: DUBLIN STATE: L2 ZIP: 2 BUSINESS PHONE: (610) 816-6640 MAIL ADDRESS: STREET 1: 1000 CONTINENTAL DRIVE STREET 2: SUITE 600 CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 FORMER COMPANY: FORMER CONFORMED NAME: Nabriva Therapeutics AG DATE OF NAME CHANGE: 20150507 CORRESP 1 filename1.htm

 

Nabriva Therapeutics plc

25-28 North Wall Quay,

IFSC, Dublin 1, Ireland

 

September 9, 2020

 

VIA EDGAR

 

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C.  20549

 

Re:                             Nabriva Therapeutics plc

Registration Statement on Form S-3

File No. 333-248530

Request for Acceleration

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Nabriva Therapeutics plc (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-248530), as amended (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern time on September 11, 2020, or as soon thereafter as practicable.

 

 

 

Very truly yours,

 

 

 

 

 

NABRIVA THERAPEUTICS PLC

 

 

 

 

 

By:

/s/ Theodore Schroeder

 

 

Name: Theodore Schroeder

 

 

Title: Chief Executive Officer